Results 141 to 150 of about 198,756 (335)

Clinical periodontal diagnosis

open access: yesPeriodontology 2000, EarlyView., 2023
Abstract Periodontal diseases include pathological conditions elicited by the presence of bacterial biofilms leading to a host response. In the diagnostic process, clinical signs such as bleeding on probing, development of periodontal pockets and gingival recessions, furcation involvement and presence of radiographic bone loss should be assessed prior ...
Giovanni E. Salvi   +5 more
wiley   +1 more source

Personalized Cancer Vaccines in the Clinical Trial Pipeline

open access: yesAsia-Pacific Journal of Clinical Oncology, EarlyView.
This study analyzes the current landscape of personalized cancer vaccine clinical trials, highlighting trends in vaccine platforms, trial phases, and geographic distribution. Peptide and dendritic cell vaccines dominate early‐stage research, with promising immune responses observed in melanoma, glioblastoma, and urothelial cancer trials.
Liudmila Iamukova, Elena Alferova
wiley   +1 more source

A case of primary cutaneous CD8+ aggressive epidermotropic cytotoxic T‐cell lymphoma

open access: yesJEADV Clinical Practice
A 65‐year‐old Japanese woman with primary cutaneous CD8+ aggressive epidermotropic cytotoxic T‐cell lymphoma, a rare type with a poor prognosis, is presented.
Tomomichi Shimizu   +9 more
doaj   +1 more source

Extreme Peripheral Blood Plasmacytosis Mimicking Plasma Cell Leukemia as a Presenting Feature of Angioimmunoblastic T-Cell Lymphoma (AITL). [PDF]

open access: yes, 2019
Angioimmunoblastic T-cell lymphoma (AITL) is one of four major subtypes of nodal peripheral T cell lymphoma, characterized by its cell of origin, the follicular helper T-cell (TFH).
Alpdogan, Onder   +7 more
core   +1 more source

Histopathological Characterization and Differential Expression of miRNAs in Male Pediatric Patients With Lichen Sclerosus

open access: yesAndrology, EarlyView.
ABSTRACT Background Lichen sclerosus is a chronic, inflammatory, scarring disease of the skin that manifests mostly in the genital region. Objective We studied the histomorphological characteristics, grade, and pattern of inflammation in male pediatric patients with lichen sclerosus.
Valerie Flammang   +10 more
wiley   +1 more source

Mycosis Fungoides: A Diagnostic Challenge

open access: yesInternational Journal of Medical Students, 2022
Background: Mycosis fungoides (MF) is the most frequent type of cutaneous T-cell lymphomas (CTCL), a heterogeneous group of non-Hodgkin lymphoma of T-cell origin. CTCLs accounts for about 4% of all non-Hodgkin lymphoma.
Siddhartha Nath   +2 more
doaj  

Multicentric B-cell lymphoma in a pygmy goat [PDF]

open access: yes, 2016
A six-year-old, male pygmy goat was referred with a sudden onset of peripheral lymphadenopathy, which initially started as enlarged inguinal lymph nodes. Clinical examination showed swollen retropharyngeal, prescapular and inguinal lymph nodes. Serologic
Chiers, Koen   +6 more
core  

The impact of Foxp3+ regulatory T‐cells on CD8+ T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley   +1 more source

Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma

open access: yesProceedings of the National Academy of Sciences of the United States of America, 1980
B. Poiesz   +5 more
semanticscholar   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy